Moraxellaceae

New Studies Highlight Activity of XERAVA™ Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant Pathogens

Retrieved on: 
Monday, June 24, 2019
Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Bacteria, Microorganisms, Chemical compounds, Gram-negative bacteria, Pyrrolidines, Carbapenem, Moraxellaceae, Eravacycline, Multiple drug resistance, Enterobacteriaceae, Acinetobacter baumannii, Antibiotic, XERAVA, Tetraphase Pharmaceuticals, Inc.

Studies Continue to Demonstrate the Potent In Vitro Activity of Eravacycline Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant Pathogens

Key Points: 
  • Studies Continue to Demonstrate the Potent In Vitro Activity of Eravacycline Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant Pathogens
    Carbapenem resistance is emerging in E. coli, including its MDR lineage.
  • tested these antibiotics against clinical E. coli isolates, including those that are carbapenem resistant, from surveillance systems encompassing multiple sites across the U.S.
  • In a large, ongoing surveillance study of XERAVA, researchers evaluated the in vitro activity of the drug against Gram-negative and Gram-positive global isolates collected in 2017, including MDR pathogens.
  • Overall, XERAVA exhibited potent in vitro activity against Enterobacteriaceae, A. baumannii and clinically important Gram-positive organisms, including resistant pathogens.

ATCC Expands Collection of Priority Pathogens to Support Antimicrobial Resistance Research

Retrieved on: 
Wednesday, May 22, 2019
Medical specialties, Medicine, Health, Healthcare-associated infections, Moraxellaceae, Drug resistance, Carbapenem, Acinetobacter, Antimicrobial resistance, Hospital-acquired infection, Community for Open Antimicrobial Drug Discovery, Multidrug-resistant Gram-negative bacteria

This expansion of ATCC's collection includes the addition of 24 strains of Acinetobacter baumannii, many of which are carbapenem-resistant priority pathogens as indicated by the World Health Organization (WHO).

Key Points: 
  • This expansion of ATCC's collection includes the addition of 24 strains of Acinetobacter baumannii, many of which are carbapenem-resistant priority pathogens as indicated by the World Health Organization (WHO).
  • These priority pathogens are remarkably resistant to multiple drugs and are a notorious contributor to hospital-acquired infections.
  • According to the WHO, antimicrobial resistance (AMR) is one of the leading public health challenges we currently face, with resistant infections being present in every country.
  • A core component of ATCC's Incredible 2020 campaign focuses on supporting global health initiatives, including tackling the antimicrobial resistance challenges associated with hospital care.

Debiopharm Awarded $2.1 Million from CARB-X in the Fight Against a Highly Resistant Nosocomial-pneumonia Causing Superbug

Retrieved on: 
Tuesday, May 14, 2019
Medical specialties, Medicine, Health, Moraxellaceae, Gram-negative bacteria, Drug resistance, Acinetobacter baumannii, Pathogenic bacteria, Antimicrobial resistance, Antibiotic, Bacteria, Community for Open Antimicrobial Drug Discovery

Debio 1454 compounds inhibit bacterial fatty acid biosynthesis, an essential pathway in many bacterial species including gram negative, drug-resistant strains.

Key Points: 
  • Debio 1454 compounds inhibit bacterial fatty acid biosynthesis, an essential pathway in many bacterial species including gram negative, drug-resistant strains.
  • "CARB-X's grant will help support the development of Debio1454, a new class of antibiotics targeting A. baumannii, one of the priority 1 critical pathogens identified by the WHO.
  • "The world urgently needs new approaches, new classes of antibiotics and rapid diagnostics to treat infections caused by drug-resistant bacteria.
  • It will take increased investment and concerted global leadership to deliver the antibiotics and other life-saving products we need to address the superbug crisis."

Global Acinetobacter Infections Pipeline Therapeutics Report 2019: Assessments by Developmental Stage, Product Type, Molecule Type, and Administration Route

Retrieved on: 
Wednesday, March 20, 2019
Moraxellaceae, Drug pipeline, Food and Drug Administration, Acinetobacter

DUBLIN, March 20, 2019 /PRNewswire/ -- The "Acinetobacter Infections - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 20, 2019 /PRNewswire/ -- The "Acinetobacter Infections - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Acinetobacter Infections development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Acinetobacter Infections pipeline products by developmental stage, product type, molecule type, and administration route.

Acinetobacter Infections Pipeline Insight Report, 2019 Edition - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 13, 2019
Health, Infectious diseases, Pharmaceutical, Moraxellaceae, Drug pipeline, Food and Drug Administration, Acinetobacter

The "Acinetobacter Infections - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acinetobacter Infections - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Acinetobacter Infections development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Acinetobacter Infections pipeline products by developmental stage, product type, molecule type, and administration route.

VenatoRx Pharmaceuticals Awarded NIAID R01 Grant to Uncover Determinants of Gram-Negative Permeability

Retrieved on: 
Thursday, February 28, 2019
Health, Infectious diseases, Pharmaceutical, Research, Science, Bacteria, Medical specialties, Infectious diseases, Gram-negative bacteria, Antibiotic-resistant bacteria, Moraxellaceae, Healthcare-associated infections, Pathogenic bacteria, Carbapenem, Acinetobacter baumannii, Multiple drug resistance, Acinetobacter

VenatoRx has the potential to receive funding of up to $7.4 million over five years if all project milestones are met.

Key Points: 
  • VenatoRx has the potential to receive funding of up to $7.4 million over five years if all project milestones are met.
  • Permeability in Gram-negative bacteria has long been considered a critical scientific problem, said Daniel C. Pevear, Ph.D. , Founder and Senior Vice President, Biology at VenatoRx.
  • This R01 grant supports a broad milestone-driven collaboration focused on developing and utilizing novel predictive assays, models and research tools to better understand penetration and efflux of small molecules in bacteria.
  • The objective of this R01 grant is to provide tools that can facilitate therapeutic discovery for Gram-negative bacterial pathogens, including carbapenem-resistant Enterobacteriaceae (CRE), multi-drug resistant (MDR) Acinetobacter baumannii and/or MDR Pseudomonas aeruginosa.